Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Izafe Group

0.251

 

SEK

 

+1.62 %

Less than 1K followers

IZAFE B

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
Compare
+1.62%
0%
+5.46%
+17.29%
+25.5%
+17.29%
-53.52%
-85.99%
-92.77%

iZafe Group is a Life Science company focused on the development and marketing of digital medical solutions. The company offers products such as Dosell, a pharmaceutical robot, and the SaaS solution Pilloxa, a connected dose bag. The products aim to reduce the risk of incorrect medication. The customers are private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group has its headquarters in Stockholm.

Read more
Market cap
80.76M SEK
Turnover
5.68K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
28.5.
2025

General meeting '25

30.8.
2025

Interim report Q2'25

3.11.
2025

Interim report Q3'25

All
Press releases
ShowingAll content types
Press release5/8/2025, 5:30 AM

April Monthly Report – Continued Growth as We Approach 1,000 Active Units

Izafe Group
Regulatory press release4/25/2025, 6:30 AM

iZafe Group Q1 Interim Report, January-March 2025

Izafe Group
Press release4/3/2025, 12:30 PM

March Monthly Update – Continued Growth and Important Progress

Izafe Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release3/21/2025, 11:00 AM

iZafe Group AB changes Certified Adviser to Carnegie Investment Bank AB

Izafe Group
Press release3/6/2025, 7:30 AM

Increased Demand and Successful Launch – iZafe Group Strengthens Its Position

Izafe Group
Press release2/27/2025, 12:15 PM

iZafe Group's Board Member Magnus Engman Purchases 200,000 Shares

Izafe Group
Press release2/24/2025, 11:00 AM

Launch of Dosell sales in Spain – A groundbreaking solution to improve medication adherence

Izafe Group
Regulatory press release2/14/2025, 7:30 AM

iZafe Group Q4 Interim Report, October-December 2024 and new forecast

Izafe Group
Press release2/6/2025, 7:30 AM

Strong Start to 2025 – iZafe Group Accelerates Dosell's Growth

Izafe Group
Regulatory press release1/13/2025, 7:42 PM

iZafe Group AB has completed a directed share issue of B shares amounting to approximately SEK 9.2 million

Izafe Group
Press release12/20/2024, 8:15 AM

The Year in Review: Reflections from iZafe Group’s CEO on 2024

Izafe Group
Press release12/6/2024, 1:00 PM

iZafe Group AB Strengthens Global Position with UMO Certification for Dosell

Izafe Group
Press release11/18/2024, 8:00 AM

Dosell Secures Large Order for 1,000 Units in the Netherlands – Order Value of SEK 3 Million and Up to SEK 400,000/Month in Recurring Revenue

Izafe Group
Press release11/14/2024, 12:30 PM

iZafe Group's CFO, Marius Sandberg, purchases 177,793 shares

Izafe Group
Regulatory press release11/1/2024, 7:30 AM

iZafe Group Q3 Interim Report, July-September 2024

Izafe Group
Press release10/23/2024, 6:30 AM

iZafe Group Celebrating a milestone: Dosell makes its grand debut in Spain with Ti Medi partnership

Izafe Group
Press release9/9/2024, 7:00 AM

iZafe Group AB and Randstad Partner in Norway to Transform Medication Management and Drive Cost Savings for Municipalities

Izafe Group
Press release9/3/2024, 8:00 AM

iZafe Group introduces a groundbreaking tripartite collaboration aimed at enhancing independence and safety in medical care

Izafe Group
Regulatory press release8/30/2024, 6:30 AM

iZafe Group Q2 Interim Report, April-June 20234

Izafe Group
Regulatory press release8/21/2024, 7:12 AM

iZafe Group secures loan of SEK 5.5 million and cancels previously issued warrants of series TO14B

Izafe Group
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.